Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2014 versus everolimus in metastatic renal cell carcinoma after VEGF-targeted therapy
2012-002874-30Phase 2Terminated
- Sponsor
- Queen Mary University of London
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in clear cell renal cell carcinoma (ccRCC) comparing AZD2014 arm with Everolimus arm (2 arms). Primary endpoint: Progression-free survival. Started Dec 2012; status: terminated.
02
Drugs
vistusertibeverolimus
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2012-002874-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002874-30.